GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.4252
-0.0112 (-2.57%)
At close: Jun 8, 2026, 4:00 PM EDT
0.4476
+0.0224 (5.27%)
Pre-market: Jun 9, 2026, 7:49 AM EDT
GT Biopharma Earnings Call Transcripts
Fiscal Year 2026
-
A modular NK cell engager platform is advancing through clinical trials for blood cancers, solid tumors, and autoimmune diseases, with promising efficacy and a strong safety profile. The technology leverages camelid nanobody innovation and targets vast oncology and autoimmune markets.
Fiscal Year 2025
-
Trispecific killer cell engager nanobodies are advancing in clinical trials for blood cancers, with a new focus on solid tumors and autoimmune diseases. The platform's unique IL-15 component drives NK cell proliferation, and preclinical data show strong efficacy in both hematologic and solid tumor models.